anti-CEA CAR T-cell therapy (Shanghai First Song Therapeutics)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-CEA CAR T-cell therapy (Shanghai First Song Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 modulatorsT lymphocytes stimulantsImmunostimulants
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsSmall Intestine CancersSolid tumoursPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Simcere Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Simcere Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSmall Intestine CancersSolid tumoursPancreatic Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A